Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Targeted Oncology3d
Advancing Thyroid Cancer Care: Molecular Testing & Targeted Therapies
Noah S. Kalman, MD, MBA, discusses the evolving role of molecular and genetic testing in thyroid cancer management.
Too Old to Operate12d
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.
Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...
Ocean Biomedical announces findings in EGFR-mutant lung cancer
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...
Cure Today2d
Breaking Down the Implications of Calquence Combination Therapy in MCL
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.
Scientists peel away the mystery of JAK enzymes, which play roles in everything from eczema to ulcerative colitis
Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...
The American Journal of Managed Care8d
Discontinuing Versus Switching BTK Inhibitors for Toxicity
Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...
Targeted Oncology21h
Jain and Participants Consider BTK Inhibitor Resistance in CLL
During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...
The Brighterside of News on MSN6h
Scientists develop microcellular drones to deliver cancer-killing drugs
Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...
Cure Today4d
FDA Approval of Calquence Combo Brings Optimism in MCL
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...